Alpine Immune Sciences to Present at Jefferies 2018 Global Healthcare Conference

SEATTLE--()--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5 2018 at 4:30 pm Eastern Time in New York, NY.

A live webcast of the presentation will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentation will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies based upon its variant Ig Domain (vIgD) technology. vIgDs are engineered to interact with multiple immune targets, including many present in the immune synapse. Alpine’s vIgDs are developed with its proprietary platform technology utilizing a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and making vIgD-based therapeutics potentially capable of treating cancer, autoimmune/inflammatory, and other diseases. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on vIgD technology, to potentially enhance engineered cellular therapies. For more information, visit www.alpineimmunesciences.com.

Contacts

For Alpine Immune Sciences, Inc.
Investor Relations
Pure Communications, Inc.
Courtney Dugan, 212-257-6723
cdugan@purecommunications.com

Contacts

For Alpine Immune Sciences, Inc.
Investor Relations
Pure Communications, Inc.
Courtney Dugan, 212-257-6723
cdugan@purecommunications.com